Tafnat EM Tablet

Tafnat EM Tablet — Emtricitabine and Tenofovir Disoproxil Fumarate for Wholesale Buyers

Two nucleoside reverse transcriptase inhibitors working together block a critical step in viral replication. Emtricitabine targets the reverse transcriptase enzyme, preventing the human immunodeficiency virus from converting its genetic material into DNA inside the host cell. Tenofovir disoproxil fumarate works through the same drug class mechanism, competing with the natural building blocks that the virus uses to build its DNA chain. Together they cut off the replication cycle before it can establish itself. The result is a well-understood, two-compound antiviral combination with decades of clinical use behind it.

That combination is what makes up Tafnat EM Tablet. Each tablet contains Emtricitabine 200mg and Tenofovir disoproxil fumarate 25mg. The manufacturer is Cipla. This is a fixed-dose combination tablet, meaning both active ingredients come in a single unit, which simplifies supply chain management for resellers and stockists handling antiretroviral product lines.

What This Product Treats

Tafnat EM Tablet is used for the management of human immunodeficiency virus type 1 infection in adults. It is also used as pre-exposure prophylaxis, reducing the risk of acquiring human immunodeficiency virus through sexual exposure or injection drug use. Both conditions fall under the same antiviral treatment category, and this product covers both. Demand across these two indications keeps reorder volumes stable for most buyers.

How the Active Compounds Work

Emtricitabine and tenofovir disoproxil fumarate both belong to the nucleoside reverse transcriptase inhibitor drug class. Once absorbed, the body converts each compound into its working form. The active forms then compete directly with natural nucleotides inside the cell. They insert themselves into the growing viral DNA chain and stop it from extending further. No further replication occurs from that point. The blocking effect applies specifically to human immunodeficiency virus reverse transcriptase, making this a targeted mechanism. It is well understood and widely studied.

Available Strengths and Pack Sizes

Tafnat EM Tablet is available in the following fixed-dose combination strength:

• Emtricitabine 200mg plus Tenofovir disoproxil fumarate 25mg

Pack size details beyond the above have not been specified in available product data. Buyers placing a bulk order for Tafnat EM Tablet should confirm current pack configurations directly with cipla or through the ordering portal at Get HIV Treatment. Bottled pricing and volume tier availability can be confirmed at the time of order.

Side Effect

The side effect of Tafnat EM Tablet is consistent with other fixed-dose combinations in the nucleoside reverse transcriptase inhibitor drug class. Commonly reported effects include nausea, headache, dizziness, and fatigue. Some cases involve changes in kidney function markers, particularly with ongoing tenofovir disoproxil fumarate exposure. Bone density changes have been noted in long-term use. Skin discolouration has been associated with emtricitabine in some populations. These characteristics are known to resellers sourcing antiviral products and are reflected in standard product documentation. The profile is stable and well documented.

Shelf Life and Storage

Tafnat EM Tablet should be stored at controlled room temperature, generally below 30 degrees Celsius, away from direct moisture and sunlight. Tablets should remain in their original sealed packaging until the point of dispensing or resale. Buyers maintaining warehouse stock should avoid high-humidity storage environments. Shelf life information should be confirmed on the batch-specific packaging at the time of receipt. Proper storage conditions protect both product integrity and reseller liability.

Pricing and Availability

Get HIV Treatment carries Tafnat EM Tablet at competitive pricing suited to resellers and stockists. Buyers looking at Tafnat EM Tablet price per bottle or bulk order quantities can access current pricing directly through the product listing. This product is available for international ordering where applicable regulations permit. Volume purchasing options are available, and consistent stock levels make it a reliable line for antiviral resellers.

Why Buyers Stock This Product

The fixed-dose format of Tafnat EM Tablet reduces complexity across the supply chain. One product covers two widely prescribed treatment needs within human immunodeficiency virus care. That drives consistent reorder demand from buyers serving both treatment and prevention markets. cipla maintains production standards expected for antiretroviral supply chains, and the compound combination behind this product has an established place in antiviral treatment globally. Resellers looking for a dependable nucleoside reverse transcriptase inhibitor combination will find the demand profile for this category strong and ongoing. Tafnat EM Tablet remains a practical stocking choice for any buyer active in the antiretroviral segment.